产前兴奋剂或托莫西汀暴露与妊娠及子代结局的系统综述与荟萃分析
该系统综述与荟萃分析纳入25项研究(23项定量分析),评估产前暴露于兴奋剂或托莫西汀与妊娠、先天畸形、围产期及神经发育结局的关联。调整后,暴露与重大先天畸形、心血管畸形、流产、早产、低出生体重、小于胎龄儿、新生儿重症监护入院及神经发育障碍均无显著关联,但5分钟Apgar评分低(aRR 1.21)及哌甲酯与心血管畸形(aRR 1.33)的关联需进一步研究。
要点
- 调整后产前兴奋剂或托莫西汀暴露不增加重大先天畸形风险(aRR 1.04)。
- 哌甲酯与心血管畸形调整后风险轻度升高(aRR 1.33),需持续关注。
- 暴露与5分钟Apgar评分低调整后仍相关(aRR 1.21),但非因果证据。
核心结论
- 产前兴奋剂或托莫西汀暴露未增加调整后重大先天畸形及多数不良妊娠、围产期和神经发育结局风险。
- 粗关联经调整后减弱,提示适应证混杂、残余混杂及母体特征的影响。
- 哌甲酯与心血管畸形及暴露与5分钟Apgar评分低的关联需进一步研究,不应视为因果伤害证据。
研究设计与样本
- 系统综述与荟萃分析,检索PubMed、Embase、Cochrane Library和Web of Science自建库至2026年3月。
- 纳入比较暴露于兴奋剂、哌甲酯或安非他明类或托莫西汀的妊娠或子代与未暴露对照的随机试验和观察性研究。
- 共纳入25项研究,其中23项贡献定量分析;采用随机效应模型分别合并未调整和调整估计值。
主要发现
- 未调整分析中暴露与重大先天畸形相关(RR 1.25,95%CI 1.14-1.37),调整后无显著关联(aRR 1.04,95%CI 0.97-1.12)。
- 调整后暴露与心血管畸形无显著关联(aRR 1.20,95%CI 0.88-1.63),但哌甲酯显示轻度升高(aRR 1.33,95%CI 1.01-1.74)。
- 调整后暴露与流产、早产、低出生体重、小于胎龄儿、新生儿重症监护入院、神经发育障碍、孤独症谱系障碍或子代注意缺陷多动障碍均无显著关联。
- 调整后暴露与5分钟Apgar评分低仍相关(aRR 1.21,95%CI 1.03-1.42)。
- 兴奋剂与较低调整后孤独症谱系障碍风险在哌甲酯特异性分析中未重复。
关键数值与推荐
- 暴露窗口包括围受孕期、孕早期、孕早期晚期、孕晚期或持续妊娠期暴露。
- 神经发育结局优先采用对照限于注意缺陷多动障碍人群的比较。
- 采用纽卡斯尔-渥太华量表评估研究质量。
临床怎么用
- 临床咨询可告知调整后多数结局风险未见显著增加,但需关注5分钟Apgar评分低及哌甲酯与心血管畸形的轻度关联。
- 不应将观察到的关联解读为因果伤害证据,需结合母体适应证及混杂因素综合评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate associations of prenatal exposure to stimulants and atomoxetine for attention-deficit/hyperactivity disorder with pregnancy, congenital, perinatal, and neurodevelopmental outcomes. DATA SOURCES: PubMed, Embase, Cochrane Library, and Web of Science were searched from inception to March 2026. Protocol was registered in the International Prospective Register of Systematic Reviews (CRD42024506319). STUDY ELIGIBILITY CRITERIA: Randomized trials and observational studies comparing pregnancies or offspring exposed to stimulant medications, methylphenidate- or amphetamine-based agents, or atomoxetine with unexposed comparators and reported outcomes were eligible. STUDY APPRAISAL AND SYNTHESIS METHODS: Reporting guidance for systematic reviews and observational meta-analyses was followed. Two reviewers screened studies, extracted data, and assessed quality with the Newcastle-Ottawa Scale. Random-effects meta-analyses pooled unadjusted and adjusted estimates separately. For neurodevelopmental outcomes, comparators restricted to attention-deficit/hyperactivity disorder populations were prioritized when available. RESULTS: Twenty-five studies were included; 23 contributed to quantitative analyses. Exposure windows included periconceptional, first-trimester, early-, late-, or continued-pregnancy exposure. Exposure was associated with major congenital malformations in unadjusted analyses (risk ratio, 1.25; 95% confidence interval, 1.14-1.37), but not after adjustment (adjusted risk ratio, 1.04; 95% confidence interval, 0.97-1.12). No adjusted association was observed with cardiovascular malformations (adjusted risk ratio, 1.20; 95% confidence interval, 0.88-1.63), although methylphenidate showed a modest increase (adjusted risk ratio, 1.33; 95% confidence interval, 1.01-1.74). In adjusted analyses, exposure was not associated with miscarriage, preterm birth, low birth weight, small for gestational age, neonatal intensive care unit admission, neurodevelopmental disorders, autism spectrum disorder, or offspring attention-deficit/hyperactivity disorder. Low 5-minute Apgar score remained associated with exposure after adjustment (adjusted risk ratio, 1.21; 95% confidence interval, 1.03-1.42). Lower adjusted autism spectrum disorder risk with stimulants was not replicated in methylphenidate-specific analyses. CONCLUSIONS: Prenatal exposure to stimulants or atomoxetine for attention-deficit/hyperactivity disorder was not associated with increased adjusted risk of major congenital malformations or most adverse pregnancy, perinatal, and neurodevelopmental outcomes. Attenuation of crude associations after adjustment suggests confounding by indication, residual confounding, and maternal characteristics. The observed associations between methylphenidate and cardiovascular malformations and between exposure and low 5-minute Apgar score warrant continued investigation but should not be interpreted as evidence of causal harm.
引用
- Komargodski R, Tillawe A, Berlin M, et al. Pregnancy and Offspring Outcomes After Prenatal Stimulant or Atomoxetine Exposure: A Systematic Review and Meta-analysis. Am J Obstet Gynecol MFM. 2026. PMID: 42887725. doi:10.1016/j.ajogmf.2026.102165
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。